Hem/Onc Roundup: FDA Approves New Myeloma Combo, Tap Water Linked to Cancer, and more

Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, the U.S. Food and Drug Administration (FDA) approved a new combination therapy for transplant-eligible patients with multiple myeloma (MM), an experimental drug showed promise for lung and kidney cancers, and more.

The FDA approved the combination of Darzalex® (daratumumab) plus Velcade® (bortezomib), thalidomide, and dexamethasone for patients with newly diagnosed MM who are eligible for autologous hematopoietic cell transplantation.

According to a press release from The North American Menopause Society, experts estimate that one in three breast cancer cases could be prevented by lifestyle modifications. The recommendations are being presented during The North American Menopause Society Annual Meeting in Chicago.

A new study has found that patients with non-small cell lung cancer and kidney cancer may benefit from pegilodecakin, a drug currently in clinical trials. Conducted by researchers from The University of Texas MD Anderson Cancer Center, this work found that when used in concert with pembrolizumab and nivolumab (two leading anti-PD-1 monoclonal antibodies), pegilodecakin was had therapeutic effects in these patients.

Drinking tap water may prove lethal, as the results of a study published in Heliyon found a toxic combination of chemical pollutants in U.S. drinking water could result in more than 100,000 new cancer cases.

A team from the University of Bath has recently used high-throughput screening techniques to evaluate tens of thousands of compounds to identify promising prostate cancer drugs. These researchers, from the University’s Departments of Chemistry and Pharmacy & Pharmacology, are analyzing the α-methylacyl-CoA racemase protein as a possible target for cancer drugs.

In case you missed it, more hem/onc headlines are featured below: